Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Sole Chimenti

Showing results (161-170 of 197) with videos related to

Pageof 20
Sort By:
Frontiers in Immunology|July 30, 2024
Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritisRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
Autoimmunity Reviews|March 23, 2024
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensusFabio Salvatore Macaluso, Flavio Caprioli, Laura Benedan, et al.
Clinical and Experimental Rheumatology|January 11, 2021
Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational studySalvatore D'Angelo, Nazzarena Malavolta, Cinzia Scambi, et al.
Frontiers in Pharmacology|May 15, 2026
Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritisRoberta Ramonda, Mariagrazia Lorenzin, Antonio Carletto, et al.
Arthritis Research & Therapy|September 28, 2024
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohortRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
Rheumatology (Oxford, England)|April 18, 2026
Phenotypic differences and treatment persistence in a large multicenter cohort of axial psoriatic arthritisGiuseppe Lopalco, Sergio Del Vescovo, Michele Maria Luchetti, et al.
Clinical and Experimental Rheumatology|December 18, 2020
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre studyGiacomo Maria Guidelli, Ombretta Viapiana, Nicoletta Luciano, et al.
Rheumatology International|June 5, 2026
Clinical associations and related factors of metabolic syndrome in systemic sclerosis: results from an observational multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)Vasiliki Liakouli, Giulio Forte, Piero Ruscitti, et al.
Scientific Reports|May 7, 2022
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritisLuca Navarini, Damiano Currado, Annalisa Marino, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Pageof 20

Showing results (161-170 of 197) with videos related to

Sort By:
Pageof 20
Frontiers in Immunology|July 30, 2024
Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritisRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
Autoimmunity Reviews|March 23, 2024
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensusFabio Salvatore Macaluso, Flavio Caprioli, Laura Benedan, et al.
Clinical and Experimental Rheumatology|January 11, 2021
Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational studySalvatore D'Angelo, Nazzarena Malavolta, Cinzia Scambi, et al.
Frontiers in Pharmacology|May 15, 2026
Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritisRoberta Ramonda, Mariagrazia Lorenzin, Antonio Carletto, et al.
Arthritis Research & Therapy|September 28, 2024
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohortRoberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, et al.
Rheumatology (Oxford, England)|April 18, 2026
Phenotypic differences and treatment persistence in a large multicenter cohort of axial psoriatic arthritisGiuseppe Lopalco, Sergio Del Vescovo, Michele Maria Luchetti, et al.
Clinical and Experimental Rheumatology|December 18, 2020
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre studyGiacomo Maria Guidelli, Ombretta Viapiana, Nicoletta Luciano, et al.
Rheumatology International|June 5, 2026
Clinical associations and related factors of metabolic syndrome in systemic sclerosis: results from an observational multicenter study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale)Vasiliki Liakouli, Giulio Forte, Piero Ruscitti, et al.
Scientific Reports|May 7, 2022
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritisLuca Navarini, Damiano Currado, Annalisa Marino, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Pageof 20